+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Glomerulonephritis and nephritis are kidney conditions that can affect both children and adults, sometimes developing after infections, as a reaction to certain medications, or as part of autoimmune diseases like lupus. In these conditions, the kidne...

Search Bar & Filters

Found 25 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating a new anti-CD19BCMA universal CAR-T cell therapy called RD06-05 in adults with various autoimmune diseases, including systemic lupus erythematosus SLE, lupus nephritis LN, ANCA-associated vasculitis AAV, anti-GBM disease, membranous nephropathy MN, systemic sclerosis SSc, idiopathic inflammatory myopathy IIM, and IgA nephropathy. This early phase 1, open-label, single-arm study aims to explore the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of this investigational cell therapy. Participants will receive the RD06-05 CAR T-cell therapy through an intravenous infusion following a preparatory lymphodepleting regimen using fludarabine and cyclophosphamide. The dose escalation design allows careful assessment of safety and biological effects. The study is planned to last up to approximately three years, with primary safety outcome monitoring over 2 years after treatment. During the study, participants will be closely monitored for adverse events, including treatment-emergent and serious side effects, as well as specific safety concerns related to cell therapy. Researchers will evaluate the therapys impact on disease activity and organ function through clinical assessments and laboratory tests. Participants will be followed for safety and efficacy outcomes until the study ends, expected in July 2028, with regular visits scheduled according to the study protocol.

Age: 18Years - 75YearsAll GendersEarly Phase 1
1 location
S

Actively Recruiting

Researchers are evaluating the safety and activity of sparsentan for treating adult patients with biopsy-confirmed immunoglobulin A nephropathy IgAN, including newly diagnosed patients who have not received prior ACEI or ARB therapy Cohort A and patients with recurrent IgAN after kidney transplantation Cohort B. This open-label, multi-center trial aims to explore sparsentans potential to protect kidney function over an extended period. In Cohort A, patients will start sparsentan at 200 mg daily, increasing to a target dose of 400 mg daily after two weeks if tolerated, with dose adjustments allowed to maintain the highest tolerable dose. Treatment will continue for 110 weeks, followed by a 4-week off-treatment follow-up. Cohort B patients will be randomly assigned to receive sparsentan plus standard care for 48 weeks or standard care alone for 24 weeks before adding sparsentan for the remaining 24 weeks, then followed by a 4-week follow-up. Additional antihypertensive treatments are allowed except for ACEIs, ARBs, aldosterone blockers, or aliskiren. Participants will undergo assessments including urine protein excretion, estimated and measured glomerular filtration rate GFR, kidney biopsy analysis using the Oxford Classification, MRI for kidney and heart function, bioimpedance for body water, and quality of life evaluations. Safety will be monitored through adverse events, lab tests, and vital signs. The primary outcome is urine proteincreatinine ratio at Week 36, with secondary outcomes assessing kidney function, proteinuria changes, and safety over up to 114 weeks.

Age: 18Years +All GendersPhase 2
6 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of three drugsfrexalimab, brivekimig, and rilzabrutinibin people aged 16 to 75 years who have primary focal segmental glomerulosclerosis FSGS or minimal change disease MCD. This Phase 2a, double-blind, placebo-controlled study aims to measure changes in proteinuria and how these drugs impact remission rates in nephrotic syndrome. Participants will be randomly assigned to one of six groups, receiving either frexalimab, brivekimig, rilzabrutinib, or a matching placebo. Treatment lasts 24 weeks, with the overall study duration up to 52 weeks. Participants will attend up to 16 visits during the study to receive the treatments and undergo assessments. Throughout the trial, participants will have their urine protein to creatinine ratio UPCR measured to assess treatment impact, particularly focusing on changes from baseline to Week 12. Other evaluations include tracking remission rates, monitoring for adverse events, and measuring drug concentrations and antibody responses up to Week 48. Participants will be closely monitored for safety and treatment effects during the study period.

Age: 16Years - 75YearsAll GendersPhase 2
79 locations
E

Actively Recruiting

Researchers are evaluating the use of pioglitazone to improve kidney outcomes in people with ANCA-associated vasculitis, a condition that affects blood vessels and involves kidney inflammation. This multicenter, randomized controlled trial includes patients with biopsy-confirmed kidney involvement of ANCA vasculitis at diagnosis. The study aims mainly to see if pioglitazone can reduce kidney damage by improving protein levels in urine and serum creatinine. It also examines effects on blood pressure, metabolic changes from steroids, vasculitis activity, and safety in this group of patients. All participants receive standard immunosuppressive treatment combining corticosteroids and rituximab. They are randomly assigned to take either pioglitazone 30 mg daily or a placebo for 26 weeks alongside the standard care. Rituximab is given weekly for four weeks as induction, then re-administered every six months. Participants follow a predefined steroid tapering schedule. Biological samples are collected at multiple points throughout the study for analysis. Participants are followed for a total of 52 weeks with visits scheduled at weeks 1, 2, 3, 4, 8, 12, 26, 38, and 52. During these visits, kidney function, proteinuria, vasculitis activity, quality of life, and safety are assessed through clinical exams, blood and urine tests, and questionnaires. The primary outcome is measured at week 26, and secondary outcomes continue through week 52 to monitor effects and safety of pioglitazone over time.

Age: 18Years - 80YearsAll GendersPhase 3
25 locations
S

Actively Recruiting

Researchers are studying anti-glomerular basement membrane disease anti-GBM disease, a rare but severe condition also known as Goodpastures disease. This observational study aims to understand the prognosis of this disease by examining how different treatment options and disease severity at diagnosis affect outcomes. The study focuses on analyzing biomarkers in blood and urine, as well as the impact of initial treatment intensity on kidney function and patient survival. The study has two parts Arm A includes patients diagnosed between January 1, 2010, and December 31, 2027, with available data on their initial treatment. Arm B includes patients diagnosed at any time with available blood or urine samples from diagnosis and information about survival six months after diagnosis. Researchers will collect data on treatments involving corticosteroids, cytotoxic agents, and plasma exchange, and evaluate various autoantibodies and markers of kidney damage and inflammation. Participants will have their kidney function and survival monitored over time, with the primary outcome being kidney survival 12 months after diagnosis. Secondary outcomes include patient survival at six and 12 months. The study uses existing patient data and biological samples to better understand the disease prognosis and treatment effects. It is sponsored by Region Skane and is expected to continue until December 2028.

Age: 18Years +All Genders
1 location
S

Actively Recruiting

Researchers are studying the tiny blood vessels in adult kidneys of patients who have proteinuria or active urinary sediment. The purpose is to better understand how these kidney issues affect microvascular structures using a special imaging method called Ultrasound Localization Microscopy ULM. This method could offer a non-invasive alternative to kidney biopsy, which is currently the standard but invasive procedure to assess kidney damage. The study uses ULM to visualize and measure kidney microvascular architecture and blood flow in adults with active urinary sediment or significant proteinuria needing kidney biopsy. Both 2D and 3D ULM imaging will be used to provide detailed views of the kidneys vascular structures. Participants may also have follow-up ULM assessments after treatment to observe changes in kidney function and perfusion. Participants will undergo ULM and contrast-enhanced ultrasound imaging along with standard laboratory tests and kidney biopsy results for comparison. The study will measure various imaging parameters up to 10 weeks after baseline, including kidney perfusion and glomeruli visualization. This observational study aims to find imaging markers that could help diagnose kidney diseases without invasive biopsy, with monitoring throughout the study duration.

Age: 18Years +All Genders
1 location
P

Actively Recruiting

Researchers are evaluating a phase 1b2a trial studying sequential alpha-beta depleted hematopoietic stem cell transplantation HSCT and kidney transplantation KT in patients who need a kidney transplant. The goal is to prevent kidney rejection after transplant without lifelong immunosuppression, reducing the risk of chronic rejection and the need for repeated transplants. This trial is for patients with conditions such as SIOD, FSGS, cystinosis, SLE nephritis, or chronic kidney disease stage 4, among others. Participants will undergo one of two conditioning regimens prior to receiving alpha-beta depleted HSCT from a donor. At least three months after HSCT, if donor myeloid engraftment is confirmed and there are no signs of kidney rejection, patients will receive a living donor kidney transplant from the same donor. Pharmacological immunosuppression used for the kidney transplant will be tapered off by day 90 after the transplant if no rejection occurs. The study begins with a safety evaluation in a small group of patients and may expand based on safety and feasibility. During the study, patients will be closely monitored for donor cell engraftment, kidney function, and any signs of graft-versus-host disease GvHD. Researchers will measure how many patients can stop immunosuppression by 90 days after kidney transplant, kidney function at one year, donor chimerism, and any acute or chronic GvHD. Follow-up will include assessments up to five years post-transplant to observe long-term outcomes such as secondary malignancies. Total participation length may extend up to a decade based on study timelines.

Age: 1Year - 30YearsAll GendersPhase 1Phase 2
1 location
O

Actively Recruiting

Researchers are studying KP104 to evaluate its efficacy, safety, pharmacokinetics, and pharmacodynamics in people with IgA nephropathy IgAN and complement 3 glomerulopathy C3G. This Phase 2 trial will begin with enrolling participants with IgAN to determine the best dose and then include participants with C3G. The study involves two stages focusing on collecting safety, immune response, drug behavior, and effectiveness data. Participants will receive KP104 as subcutaneous injections either weekly or biweekly. Initially, participants with IgAN will be randomized to two dose levels during Stage 1 to identify the optimal biologic dose OBD. Once the OBD is established, participants in Stage 2 with IgAN or C3G will receive KP104 at that dose for a minimum of 47 to 48 weeks. Participants may switch dosing schedules if still in treatment during Stage 1. Throughout the study, participants will be regularly monitored with urine protein and kidney function tests, as well as assessments of drug levels, immune response, and safety events. The primary measurement is the percent change in 24-hour urinary protein creatinine ratio at Week 24 for C3G participants in Stage 2. Adverse events and kidney filtration rates will also be tracked for up to 56 weeks. The total study duration extends to December 2028.

Age: 18Years - 75YearsAll GendersPhase 2
1 location
S

Actively Recruiting

This research investigates the connection between altered tubulo-interstitial metabolism and how quickly kidney function worsens in various kidney diseases. It compares patients with ANCA vasculitis and rapidly progressive glomerulonephritis characterized by crescent formation to six other groups of patients with different kidney conditions, including extramembranous glomerulonephritis, minimal change nephropathy, interstitial nephropathy, IgA mesangial glomerulopathy, diabetic nephropathy, and collapsing focal segmental hyalinosis. Participants include those diagnosed through kidney biopsy with ANCA vasculitis marked by anti-proteinase 3 or anti-myeloperoxidase antibodies, as well as control groups with other specified kidney diseases confirmed by biopsy. The study observes these groups without interventions, focusing on natural disease progression and metabolic changes over time. Throughout the study, participants undergo assessments including spatial lipidomics, co-staining of kidney tubular markers, immunofluorescence and spatial transcriptomics for PPAR-gamma, and various analyses such as lipidomic, metabolomic, and transcriptomic tests. Kidney function measures like glomerular filtration rate and proteinuria are monitored over one year. Baseline evaluations include fibrosis quantification, capillary density, and immune cell markers. Safety and health data such as blood counts, heart rate, and blood pressure are also recorded, with follow-up continuing until one year after enrollment.

Age: 18Years - 90YearsAll Genders
1 location
P

Actively Recruiting

Researchers are evaluating aliskiren, a direct renin inhibitor, as a new treatment option for patients with C3 glomerulopathy, a kidney disease caused by complement system activation. This study compares aliskiren to the current standard treatment, enalapril, an angiotensin converting enzyme inhibitor ACEi. The goal is to see if aliskiren can better reduce complement activation in the kidneys, which may stabilize or improve kidney function. This is a phase 2, randomized, open-label, controlled cross-over trial involving patients with this complement-mediated renal disease. Participants will be randomly assigned to start treatment with either aliskiren tablets 150-300 mg daily or enalapril tablets 2.5-20 mg daily for the first 6 months. After this period, they will switch to the other treatment for the next 2.5 years, completing a total of 3 years of treatment. Dosing schedules may vary between once or twice daily depending on the medication and patient weight. The study also includes an extension phase with repeat kidney biopsies to assess complement deposition and kidney tissue changes. During the study, patients will have routine follow-up visits every 3 months with their own nephrologist. These visits will include blood and urine tests to monitor kidney function, protein levels, renin and complement system activity using various assays. Kidney biopsies will be performed at the start and again after 1 to 3 years to evaluate treatment effects on kidney structure. The study measures primary outcomes such as serum C3 levels and complement deposits in the kidneys, along with secondary outcomes like proteinuria, blood pressure, and other complement activation markers.

Age: 6Years +All GendersPhase 2
4 locations

1-10 of 25

1